NCT03737136View on ClinicalTrials.gov

Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

May 30, 2024

Study Completion Date

September 1, 2025

Conditions
Antibody-mediated Rejection
Interventions
DRUG

Bortezomib

one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)

Trial Locations (1)

Unknown

SBMU, Tehran

All Listed Sponsors
lead

Shahid Beheshti University of Medical Sciences

OTHER

NCT03737136 - Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR | Biotech Hunter | Biotech Hunter